Olivia Vizier

psych

First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder

MindMed announced the first patient had been dosed in the first-ever phase 3 trial of lysergic acid-diethylamide (LSD) for generalized anxiety disorder (GAD). MindMed is currently the furthest along in clinical trials exploring LSD as a treatment in multiple psychiatric indications, including major depressive disorder.

First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder Read More »

Biotech TV

Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies

V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.

Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies Read More »

Biotech TV

The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP

CEO Rajesh Devraj describes the company’s focus on membrane protein function and normalizing it with small molecules, in this case for cholestasis and cholangitis associated with liver diseases.

The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP Read More »

Biotech TV

London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE – both in the acute and prophylaxis settings

CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully developing an oral therapy could set Pharvaris apart.

London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE – both in the acute and prophylaxis settings Read More »

CMO 360

A CMO’s Perspective on Designing Clinical Trials for a Psychedelic-Derived Drug Candidate

From a trial design perspective, we’ve tried to make these trials as familiar to stakeholders – regulators, prescribers, payors – as possible. What’s remarkable here are the qualities of the drug that we’re developing, MM120, a pharmaceutical formulation of LSD; we don’t need to do anything inconsistent with the history of psychiatric clinical trials beyond

A CMO’s Perspective on Designing Clinical Trials for a Psychedelic-Derived Drug Candidate Read More »

Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance

At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”

Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance Read More »